Seifert W - Search Results

1

Exact Solution of a Constraint Optimization Problem for the Thermoelectric Figure of Merit.

Seifert W, Pluschke V. Seifert W, et al. Materials (Basel). 2012 Mar 21;5(3):528-539. doi: 10.3390/ma5030528. Materials (Basel). 2012. PMID: 28817061 Free PMC article.

2

Thermoelectric cooler concepts and the limit for maximum cooling.

Seifert W, Pluschke V, Hinsche NF. Seifert W, et al. J Phys Condens Matter. 2014 Jun 25;26(25):255803. doi: 10.1088/0953-8984/26/25/255803. Epub 2014 Jun 5. J Phys Condens Matter. 2014. PMID: 24899626

3

EBIC and luminescence studies of defects in solar cells.

Breitenstein O, Bauer J, Kittler M, Arguirov T, Seifert W. Breitenstein O, et al. Among authors: seifert w. Scanning. 2008 Jul-Aug;30(4):331-8. doi: 10.1002/sca.20112. Scanning. 2008. PMID: 18561253 Free article.

4

Regular dislocation networks in silicon as a tool for nanostructure devices used in optics, biology, and electronics.

Kittler M, Yu X, Mchedlidze T, Arguirov T, Vyvenko OF, Seifert W, Reiche M, Wilhelm T, Seibt M, Voss O, Wolff A, Fritzsche W. Kittler M, et al. Among authors: seifert w. Small. 2007 Jun;3(6):964-73. doi: 10.1002/smll.200600539. Small. 2007. PMID: 17429814

5

Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review.

Ay C, Napolitano M, Hassoun A, Tomic R, Martin C, Seifert W, Pinachyan K, Oldenburg J. Ay C, et al. Among authors: seifert w. Haemophilia. 2024 Mar 29. doi: 10.1111/hae.15001. Online ahead of print. Haemophilia. 2024. PMID: 38549463 Review.

6

Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.

Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, von Depka Prondzinski M, Wang R, McKeand W, Seifert W, Oldenburg J. Lemons R, et al. Among authors: seifert w. TH Open. 2024 Mar 26;8(1):e155-e163. doi: 10.1055/s-0044-1781466. eCollection 2024 Jan. TH Open. 2024. PMID: 38532939 Free PMC article.

7

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients.

Pabinger I, Lissitchkov T, Nagao A, Lepatan LM, Li Y, Seifert W, Mancuso ME. Pabinger I, et al. Among authors: seifert w. Res Pract Thromb Haemost. 2023 May 25;7(4):100195. doi: 10.1016/j.rpth.2023.100195. eCollection 2023 May. Res Pract Thromb Haemost. 2023. PMID: 37538501 Free PMC article.

8

Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.

Laws HJ, Fukutake K, Lopez-Fernandez MF, Li Y, Seifert W, Tagliaferri A. Laws HJ, et al. Among authors: seifert w. Eur J Haematol. 2023 Aug;111(2):293-299. doi: 10.1111/ejh.14010. Epub 2023 May 26. Eur J Haematol. 2023. PMID: 37232041

9

Disease relevance of rare VPS13B missense variants for neurodevelopmental Cohen syndrome.

Zorn M, Kühnisch J, Bachmann S, Seifert W. Zorn M, et al. Among authors: seifert w. Sci Rep. 2022 Jun 11;12(1):9686. doi: 10.1038/s41598-022-13717-w. Sci Rep. 2022. PMID: 35690661 Free PMC article.

10

IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.

Escobar M, Mancuso ME, Hermans C, Leissinger C, Seifert W, Li Y, McKeand W, Oldenburg J. Escobar M, et al. Among authors: seifert w. J Clin Med. 2022 Feb 18;11(4):1071. doi: 10.3390/jcm11041071. J Clin Med. 2022. PMID: 35207344 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page